Incannex Healthcare (IXHL) Cash from Investing Activities (2023 - 2026)
Incannex Healthcare (IXHL) posted quarterly Cash from Investing Activities of -$18000.0 for Q1 2026, down 350.0% on a QoQ basis from -$4000.0 in Q4 2025.
Incannex Healthcare (IXHL) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Incannex Healthcare (IXHL) has reported Cash from Investing Activities for 4 consecutive years, with -$18000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$18000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$64000.0 (down 14.29% YoY) and the FY2025 annual result came in at -$8000.0, up 97.11% from the prior year.
- Cash from Investing Activities slipped to -$18000.0 in Q1 2026 per IXHL's latest filing, from -$4000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for IXHL reached as high as $6000.0 in Q1 2024 and fell as low as -$221000.0 in Q3 2023.
- A 4-year average of -$60444.4 and a median of -$32000.0 in 2023 frame the typical range for Cash from Investing Activities.
- The largest YoY upside for Cash from Investing Activities was 118.75% in 2024 against a maximum downside of 98.25% in 2024.
- Year by year, Cash from Investing Activities stood at -$59000.0 in 2023, then soared by 94.92% to -$3000.0 in 2024, then sank by 33.33% to -$4000.0 in 2025, then sank by 350.0% to -$18000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$18000.0, -$4000.0, and -$42000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Incannex Healthcare | 37.29 Mn | 37.29 Mn | - | -18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18,000.00 |
| Mar 31, 2026 | -18,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Sep 30, 2025 | -42,000.00 |
| Sep 30, 2025 | -42,000.00 |
| Jun 30, 2024 | -3,000.00 |
| Jun 30, 2024 | -3,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Dec 31, 2023 | -59,000.00 |
| Dec 31, 2023 | -59,000.00 |
| Sep 30, 2023 | -221,000.00 |
| Sep 30, 2023 | -221,000.00 |
| Jun 30, 2023 | -171,000.00 |
| Jun 30, 2023 | -171,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Mar 31, 2023 | -32,000.00 |